We are live on ! Find out more
VIVO

Meridian Bioscience Inc

Delisted

VIVO was delisted on the 30th of January, 2023.

160 hedge funds and large institutions have $621M invested in Meridian Bioscience Inc in 2014 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 52 increasing their positions, 59 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 22

1% less funds holding

Funds holding: 161160 (-1)

11% less capital invested

Capital invested by funds: $695M → $621M (-$74.1M)

12% less repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 59

96% less call options, than puts

Call options by funds: $41K | Put options by funds: $1.06M

Holders
160
Holders Change
-1
Holders Change %
-0.62%
% of All Funds
4.27%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
22
Increased
52
Reduced
59
Closed
22
Calls
$41K
Puts
$1.06M
Net Calls
-$1.02M
Net Calls Change
+$782K
Name Holding Trade Value Shares
Change
Change in
Stake
BCM
1
Brown Capital Management
Maryland
$73.4M -$1.19M -69,440 -2%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$57.1M -$257K -14,957 -0.4%
Neuberger Berman Group
3
Neuberger Berman Group
New York
$49.2M -$2.54M -147,904 -5%
Vanguard Group
4
Vanguard Group
Pennsylvania
$44.5M -$2.41M -140,401 -5%
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$44M +$739K +43,100 +2%
BFA
6
BlackRock Fund Advisors
California
$38M +$3.97M +231,542 +11%
CPCM
7
Clifton Park Capital Management
Delaware
$21.1M -$1.99M -115,900 -8%
BIT
8
BlackRock Institutional Trust
California
$18.6M -$103K -5,980 -0.5%
Renaissance Technologies
9
Renaissance Technologies
New York
$15.8M +$2.87M +167,300 +21%
State Street
10
State Street
Massachusetts
$14.2M +$304K +17,719 +2%
PP
11
Prudential plc
United Kingdom
$12.6M +$5.95M +346,800 +83%
Dimensional Fund Advisors
12
Dimensional Fund Advisors
Texas
$12.5M +$1.7M +99,290 +15%
New York State Common Retirement Fund
13
New York State Common Retirement Fund
New York
$12.1M
Schroder Investment Management Group
14
Schroder Investment Management Group
United Kingdom
$11.6M -$44.6K -2,600 -0.4%
Bank of New York Mellon
15
Bank of New York Mellon
New York
$10.6M -$25.5M -1,486,479 -70%
Norges Bank
16
Norges Bank
Norway
$10.1M +$355K +20,721 +4%
Millennium Management
17
Millennium Management
New York
$9.52M +$4.64M +270,217 +88%
CIC
18
Crawford Investment Counsel
Georgia
$8.91M -$267K -15,541 -3%
Northern Trust
19
Northern Trust
Illinois
$8.71M -$1.29M -75,364 -12%
ACM
20
Atlanta Capital Management
Georgia
$8.39M -$9.92M -578,052 -53%
Fifth Third Bancorp
21
Fifth Third Bancorp
Ohio
$7.88M +$36.9K +2,153 +0.5%
Wells Fargo
22
Wells Fargo
California
$5.8M +$3.53M +205,890 +140%
Deutsche Bank
23
Deutsche Bank
Germany
$5.22M +$1.27M +74,225 +31%
Morgan Stanley
24
Morgan Stanley
New York
$4.46M +$3.62M +211,118 +353%
RA
25
Royce & Associates
New York
$4.44M +$1.3M +75,500 +39%

VIVO Hedge Fund Activity: Q4 2014 in Review

160 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q4 2014, worth a combined $621M — down 11% from $695M a quarter earlier.

Fund positioning in VIVO was balanced in Q4 2014: 22 funds opened new positions, 22 closed out, 52 added to existing stakes and 59 trimmed.

The largest buyer was Prudential plc, adding an estimated $5.95M. The largest seller was Bank of New York Mellon, cutting an estimated $25.5M.

  • 160 institutional investors held Meridian Bioscience Inc (VIVO) as of Q4 2014, down from 161 in Q3 2014.
  • Funds reported $621M of Meridian Bioscience Inc stock for Q4 2014, down 11% quarter-over-quarter.
  • 22 funds opened new Meridian Bioscience Inc positions in Q4 2014 and 22 closed out, a net change of 0 holders.
  • The largest Meridian Bioscience Inc buyer in Q4 2014 was Prudential plc, an estimated $5.95M added.
  • The largest Meridian Bioscience Inc seller in Q4 2014 was Bank of New York Mellon, an estimated $25.5M sold.

Based on aggregated 13F filings for Q4 2014.